Boston Scientific spends $70 million on MinTec
This article was originally published in Clinica
Executive Summary
Boston Scientific, the US manufacturer of minimally invasive products, has purchased privately-owned MinTec for $70 million in cash. MinTec, which has its headquarters in the Bahamas, is developing stent graft technology for the repair of abdominal aortic aneurysms, peripheral aneurysms and peripheral vascular occlusive disease. Boston says it has been working with MinTec for some time on the development of a bifurcated stent graft and delivery system for the repair of AAAs using the technology of its Meadox division.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.